Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) and Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.
Insider and Institutional Ownership
36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are owned by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are owned by insiders. Comparatively, 22.0% of Bicycle Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Aurinia Pharmaceuticals and Bicycle Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aurinia Pharmaceuticals | 0 | 3 | 2 | 1 | 2.67 |
| Bicycle Therapeutics | 1 | 4 | 5 | 0 | 2.40 |
Aurinia Pharmaceuticals presently has a consensus target price of $17.33, indicating a potential upside of 10.19%. Bicycle Therapeutics has a consensus target price of $13.57, indicating a potential upside of 302.71%. Given Bicycle Therapeutics’ higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than Aurinia Pharmaceuticals.
Earnings and Valuation
This table compares Aurinia Pharmaceuticals and Bicycle Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aurinia Pharmaceuticals | $321.74 million | 6.55 | $287.20 million | $2.29 | 6.87 |
| Bicycle Therapeutics | $83.53 million | 2.83 | -$218.96 million | ($2.03) | -1.66 |
Aurinia Pharmaceuticals has higher revenue and earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Aurinia Pharmaceuticals has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500.
Profitability
This table compares Aurinia Pharmaceuticals and Bicycle Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aurinia Pharmaceuticals | 97.68% | 22.99% | 17.99% |
| Bicycle Therapeutics | -169.75% | -26.02% | -22.30% |
Summary
Aurinia Pharmaceuticals beats Bicycle Therapeutics on 10 of the 15 factors compared between the two stocks.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing treatments for autoimmune diseases. The Canadian company’s work has centered on therapies for conditions that can affect the kidneys and other organs. Its lead product, Lupkynis (voclosporin), is an oral medicine approved in the United States to treat adults with active lupus nephritis, a kidney complication of systemic lupus erythematosus. It is used in combination with background immunosuppressive therapy. Aurinia, formerly known as Isotechnika, developed voclosporin as a treatment for lupus nephritis.
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a focus on cancer. Founded in 2009, the company grew out of research at the University of Cambridge in the United Kingdom and has operations in Cambridge, UK, and Cambridge, Massachusetts. The company’s proprietary Bicycle platform creates small, constrained peptides that can bind to specific biological targets. Bicycle Therapeutics is using this technology to develop treatments that may be designed to reach targets that are difficult for conventional drugs to access.
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
